Literature DB >> 2253218

Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice.

L H Pai1, D J FitzGerald, M Tepper, B Schacter, G Spitalny, I Pastan.   

Abstract

Immunotoxins are potent cell-killing agents that may be useful in the treatment of cancer. The early production of neutralizing antibodies to immunotoxins is one of the major limiting factors for their use in humans. 15-Deoxyspergualin (DSG), a derivative of spergualin, which is a metabolite of Bacillus laterosporus, has been found to have immunosuppressive activity in rodents, dogs, and primates. We examined the suppressive activity of DSG on the antibody response to Pseudomonas exotoxin in mice by enzyme-linked immunosorbent assay. Male BDF1 mice were immunized with a single dose of a nontoxic mutant of Pseudomonas exotoxin (40 micrograms) and then treated with i.p. injections of DSF at a dose of 10 mg/kg for 3 days. Although antibodies to Pseudomonas exotoxin were observed within 7 days in the control group, there was complete suppression of antibody production in the DSG-treated group. Immunosuppression has also been observed in animals immunized with multiple doses (10 mg x 7 d) of Pseudomonas exotoxin and treated with DSG at a dose of 5 mg/kg for 21 days. Similar immunosuppression was observed in mice given multiple doses of the immunotoxin, anti-Tac-LysPE40. We conclude that the immunosuppressive activity of DSG may be useful in increasing the duration of immunotoxin treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253218

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  15 in total

Review 1.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 2.  The development of immunoconjugates for targeted cancer therapy.

Authors:  Brandon G Smaglo; Dalal Aldeghaither; Louis M Weiner
Journal:  Nat Rev Clin Oncol       Date:  2014-09-30       Impact factor: 66.675

3.  Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.

Authors:  Seth H Pincus; Kejing Song; Grace A Maresh; Anderson Frank; David Worthylake; Hye-Kyung Chung; Patricia Polacino; Dean H Hamer; Cody P Coyne; Michael G Rosenblum; John W Marks; Gang Chen; Deborah Weiss; Victor Ghetie; Ellen S Vitetta; James E Robinson; Shiu-Lok Hu
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

4.  Immunotoxins: a promising treatment modality for metastatic melanoma?

Authors:  Karianne Risberg; Oystein Fodstad; Yvonne Andersson
Journal:  Ochsner J       Date:  2010

5.  Inhibition of cell growth through inactivation of eukaryotic translation initiation factor 5A (eIF5A) by deoxyspergualin.

Authors:  Kazuhiro Nishimura; Yuji Ohki; Tomomi Fukuchi-Shimogori; Kaori Sakata; Kan Saiga; Takanobu Beppu; Akira Shirahata; Keiko Kashiwagi; Kazuei Igarashi
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

6.  Phase II study of deoxyspergualin in metastatic breast cancer.

Authors:  K Dhingra; V Valero; L Gutierrez; R Theriault; D Booser; F Holmes; A Buzdar; G Fraschini; G Hortobagyi
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

7.  Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.

Authors:  Robert Sarnovsky; Tara Tendler; Matheusz Makowski; Maureen Kiley; Antonella Antignani; Roberta Traini; Jingli Zhang; Raffit Hassan; David J FitzGerald
Journal:  Cancer Immunol Immunother       Date:  2009-11-29       Impact factor: 6.968

8.  A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer.

Authors:  D G Pfister; D Bajorin; R J Motzer; H Scher; C Louison; L Harrison; J Shah; E Strong; G Bosl
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

9.  Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.

Authors:  Xiaojing Cong; Christian Cremer; Thomas Nachreiner; Stefan Barth; Paolo Carloni
Journal:  Protein Sci       Date:  2016-05-19       Impact factor: 6.725

10.  Tumor marker disaccharide D-Gal-beta 1, 3-GalNAc complexed to heat-labile enterotoxin from Escherichia coli.

Authors:  F van den Akker; E Steensma; W G Hol
Journal:  Protein Sci       Date:  1996-06       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.